|
|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
relating to the availability of antipsychotic prescription drugs |
|
under the vendor drug program and Medicaid managed care. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. Section 531.073, Government Code, is amended by |
|
amending Subsection (a) and adding Subsections (a-3) and (a-4) to |
|
read as follows: |
|
(a) The executive commissioner, in the rules and standards |
|
governing the Medicaid vendor drug program and the child health |
|
plan program, shall require prior authorization for the |
|
reimbursement of a drug that is not included in the appropriate |
|
preferred drug list adopted under Section 531.072, except for any |
|
drug exempted from prior authorization requirements by federal law |
|
and except as provided by Subsections (a-3) and [Subsection] (j). |
|
The executive commissioner may require prior authorization for the |
|
reimbursement of a drug provided through any other state program |
|
administered by the commission or a state health and human services |
|
agency, including a community mental health center and a state |
|
mental health hospital if the commission adopts preferred drug |
|
lists under Section 531.072 that apply to those facilities and the |
|
drug is not included in the appropriate list. The executive |
|
commissioner shall require that the prior authorization be obtained |
|
by the prescribing physician or prescribing practitioner. |
|
(a-3) The executive commissioner, in the rules and |
|
standards governing the vendor drug program, may not require |
|
clinical, nonpreferred, or other prior authorization for an |
|
antipsychotic drug prescribed to an adult patient if: |
|
(1) the patient has a diagnosed mental illness, as |
|
defined by Section 571.003, Health and Safety Code, for which the |
|
drug is prescribed; |
|
(2) the prescribing physician or other health care |
|
provider determines there is a medical necessity for prescribing |
|
the drug based on: |
|
(A) the treatment failure of a comparable drug on |
|
an appropriate preferred drug list or within any subclass of a drug |
|
on that list; |
|
(B) medical contraindication of a drug on an |
|
appropriate preferred drug list; or |
|
(C) an allergic reaction to a drug on an |
|
appropriate preferred drug list; |
|
(3) the prescribing physician or other health care |
|
provider determines, in consultation with the patient, that the |
|
drug is the most appropriate course of treatment for the patient's |
|
mental illness; |
|
(4) the drug is approved for use by the United States |
|
Food and Drug Administration; |
|
(5) the prescribing physician or other health care |
|
provider clearly indicates on the prescription that the drug must |
|
be dispensed as written; and |
|
(6) the prescribing physician or other health care |
|
provider documents in the patient's health care record that each |
|
requirement under this subsection has been satisfied. |
|
(a-4) Subsection (a-3) does not affect: |
|
(1) the authority of a pharmacist to dispense the |
|
generic equivalent or interchangeable biological product of a |
|
prescription drug in accordance with Subchapter A, Chapter 562, |
|
Occupations Code; or |
|
(2) any drug utilization review requirements |
|
prescribed by state or federal law. |
|
SECTION 2. Section 533.005(a), Government Code, is amended |
|
to read as follows: |
|
(a) A contract between a managed care organization and the |
|
commission for the organization to provide health care services to |
|
recipients must contain: |
|
(1) procedures to ensure accountability to the state |
|
for the provision of health care services, including procedures for |
|
financial reporting, quality assurance, utilization review, and |
|
assurance of contract and subcontract compliance; |
|
(2) capitation rates that ensure the cost-effective |
|
provision of quality health care; |
|
(3) a requirement that the managed care organization |
|
provide ready access to a person who assists recipients in |
|
resolving issues relating to enrollment, plan administration, |
|
education and training, access to services, and grievance |
|
procedures; |
|
(4) a requirement that the managed care organization |
|
provide ready access to a person who assists providers in resolving |
|
issues relating to payment, plan administration, education and |
|
training, and grievance procedures; |
|
(5) a requirement that the managed care organization |
|
provide information and referral about the availability of |
|
educational, social, and other community services that could |
|
benefit a recipient; |
|
(6) procedures for recipient outreach and education; |
|
(7) a requirement that the managed care organization |
|
make payment to a physician or provider for health care services |
|
rendered to a recipient under a managed care plan on any claim for |
|
payment that is received with documentation reasonably necessary |
|
for the managed care organization to process the claim: |
|
(A) not later than: |
|
(i) the 10th day after the date the claim is |
|
received if the claim relates to services provided by a nursing |
|
facility, intermediate care facility, or group home; |
|
(ii) the 30th day after the date the claim |
|
is received if the claim relates to the provision of long-term |
|
services and supports not subject to Subparagraph (i); and |
|
(iii) the 45th day after the date the claim |
|
is received if the claim is not subject to Subparagraph (i) or (ii); |
|
or |
|
(B) within a period, not to exceed 60 days, |
|
specified by a written agreement between the physician or provider |
|
and the managed care organization; |
|
(7-a) a requirement that the managed care organization |
|
demonstrate to the commission that the organization pays claims |
|
described by Subdivision (7)(A)(ii) on average not later than the |
|
21st day after the date the claim is received by the organization; |
|
(8) a requirement that the commission, on the date of a |
|
recipient's enrollment in a managed care plan issued by the managed |
|
care organization, inform the organization of the recipient's |
|
Medicaid certification date; |
|
(9) a requirement that the managed care organization |
|
comply with Section 533.006 as a condition of contract retention |
|
and renewal; |
|
(10) a requirement that the managed care organization |
|
provide the information required by Section 533.012 and otherwise |
|
comply and cooperate with the commission's office of inspector |
|
general and the office of the attorney general; |
|
(11) a requirement that the managed care |
|
organization's usages of out-of-network providers or groups of |
|
out-of-network providers may not exceed limits for those usages |
|
relating to total inpatient admissions, total outpatient services, |
|
and emergency room admissions determined by the commission; |
|
(12) if the commission finds that a managed care |
|
organization has violated Subdivision (11), a requirement that the |
|
managed care organization reimburse an out-of-network provider for |
|
health care services at a rate that is equal to the allowable rate |
|
for those services, as determined under Sections 32.028 and |
|
32.0281, Human Resources Code; |
|
(13) a requirement that, notwithstanding any other |
|
law, including Sections 843.312 and 1301.052, Insurance Code, the |
|
organization: |
|
(A) use advanced practice registered nurses and |
|
physician assistants in addition to physicians as primary care |
|
providers to increase the availability of primary care providers in |
|
the organization's provider network; and |
|
(B) treat advanced practice registered nurses |
|
and physician assistants in the same manner as primary care |
|
physicians with regard to: |
|
(i) selection and assignment as primary |
|
care providers; |
|
(ii) inclusion as primary care providers in |
|
the organization's provider network; and |
|
(iii) inclusion as primary care providers |
|
in any provider network directory maintained by the organization; |
|
(14) a requirement that the managed care organization |
|
reimburse a federally qualified health center or rural health |
|
clinic for health care services provided to a recipient outside of |
|
regular business hours, including on a weekend day or holiday, at a |
|
rate that is equal to the allowable rate for those services as |
|
determined under Section 32.028, Human Resources Code, if the |
|
recipient does not have a referral from the recipient's primary |
|
care physician; |
|
(15) a requirement that the managed care organization |
|
develop, implement, and maintain a system for tracking and |
|
resolving all provider appeals related to claims payment, including |
|
a process that will require: |
|
(A) a tracking mechanism to document the status |
|
and final disposition of each provider's claims payment appeal; |
|
(B) the contracting with physicians who are not |
|
network providers and who are of the same or related specialty as |
|
the appealing physician to resolve claims disputes related to |
|
denial on the basis of medical necessity that remain unresolved |
|
subsequent to a provider appeal; |
|
(C) the determination of the physician resolving |
|
the dispute to be binding on the managed care organization and |
|
provider; and |
|
(D) the managed care organization to allow a |
|
provider with a claim that has not been paid before the time |
|
prescribed by Subdivision (7)(A)(ii) to initiate an appeal of that |
|
claim; |
|
(16) a requirement that a medical director who is |
|
authorized to make medical necessity determinations is available to |
|
the region where the managed care organization provides health care |
|
services; |
|
(17) a requirement that the managed care organization |
|
ensure that a medical director and patient care coordinators and |
|
provider and recipient support services personnel are located in |
|
the South Texas service region, if the managed care organization |
|
provides a managed care plan in that region; |
|
(18) a requirement that the managed care organization |
|
provide special programs and materials for recipients with limited |
|
English proficiency or low literacy skills; |
|
(19) a requirement that the managed care organization |
|
develop and establish a process for responding to provider appeals |
|
in the region where the organization provides health care services; |
|
(20) a requirement that the managed care organization: |
|
(A) develop and submit to the commission, before |
|
the organization begins to provide health care services to |
|
recipients, a comprehensive plan that describes how the |
|
organization's provider network complies with the provider access |
|
standards established under Section 533.0061; |
|
(B) as a condition of contract retention and |
|
renewal: |
|
(i) continue to comply with the provider |
|
access standards established under Section 533.0061; and |
|
(ii) make substantial efforts, as |
|
determined by the commission, to mitigate or remedy any |
|
noncompliance with the provider access standards established under |
|
Section 533.0061; |
|
(C) pay liquidated damages for each failure, as |
|
determined by the commission, to comply with the provider access |
|
standards established under Section 533.0061 in amounts that are |
|
reasonably related to the noncompliance; and |
|
(D) regularly, as determined by the commission, |
|
submit to the commission and make available to the public a report |
|
containing data on the sufficiency of the organization's provider |
|
network with regard to providing the care and services described |
|
under Section 533.0061(a) and specific data with respect to access |
|
to primary care, specialty care, long-term services and supports, |
|
nursing services, and therapy services on the average length of |
|
time between: |
|
(i) the date a provider requests prior |
|
authorization for the care or service and the date the organization |
|
approves or denies the request; and |
|
(ii) the date the organization approves a |
|
request for prior authorization for the care or service and the date |
|
the care or service is initiated; |
|
(21) a requirement that the managed care organization |
|
demonstrate to the commission, before the organization begins to |
|
provide health care services to recipients, that, subject to the |
|
provider access standards established under Section 533.0061: |
|
(A) the organization's provider network has the |
|
capacity to serve the number of recipients expected to enroll in a |
|
managed care plan offered by the organization; |
|
(B) the organization's provider network |
|
includes: |
|
(i) a sufficient number of primary care |
|
providers; |
|
(ii) a sufficient variety of provider |
|
types; |
|
(iii) a sufficient number of providers of |
|
long-term services and supports and specialty pediatric care |
|
providers of home and community-based services; and |
|
(iv) providers located throughout the |
|
region where the organization will provide health care services; |
|
and |
|
(C) health care services will be accessible to |
|
recipients through the organization's provider network to a |
|
comparable extent that health care services would be available to |
|
recipients under a fee-for-service or primary care case management |
|
model of Medicaid managed care; |
|
(22) a requirement that the managed care organization |
|
develop a monitoring program for measuring the quality of the |
|
health care services provided by the organization's provider |
|
network that: |
|
(A) incorporates the National Committee for |
|
Quality Assurance's Healthcare Effectiveness Data and Information |
|
Set (HEDIS) measures or, as applicable, the national core |
|
indicators adult consumer survey and the national core indicators |
|
child family survey for individuals with an intellectual or |
|
developmental disability; |
|
(B) focuses on measuring outcomes; and |
|
(C) includes the collection and analysis of |
|
clinical data relating to prenatal care, preventive care, mental |
|
health care, and the treatment of acute and chronic health |
|
conditions and substance abuse; |
|
(23) subject to Subsection (a-1), a requirement that |
|
the managed care organization develop, implement, and maintain an |
|
outpatient pharmacy benefit plan for its enrolled recipients: |
|
(A) that, except as provided by Paragraph |
|
(L)(ii), exclusively employs the vendor drug program formulary and |
|
preserves the state's ability to reduce waste, fraud, and abuse |
|
under Medicaid; |
|
(B) that adheres to the applicable preferred drug |
|
list adopted by the commission under Section 531.072; |
|
(C) that, except as provided by Paragraph (L)(i), |
|
includes the prior authorization procedures and requirements |
|
prescribed by or implemented under Sections 531.073(b), (c), and |
|
(g) for the vendor drug program; |
|
(C-1) that does not require a clinical, |
|
nonpreferred, or other prior authorization for any antiretroviral |
|
drug, as defined by Section 531.073, or a step therapy or other |
|
protocol, that could restrict or delay the dispensing of the drug |
|
except to minimize fraud, waste, or abuse; |
|
(C-2) that does not require a clinical, |
|
nonpreferred, or other prior authorization for an antipsychotic |
|
drug prescribed to an adult recipient if the requirements of |
|
Section 531.073(a-3) are met; |
|
(D) for purposes of which the managed care |
|
organization: |
|
(i) may not negotiate or collect rebates |
|
associated with pharmacy products on the vendor drug program |
|
formulary; and |
|
(ii) may not receive drug rebate or pricing |
|
information that is confidential under Section 531.071; |
|
(E) that complies with the prohibition under |
|
Section 531.089; |
|
(F) under which the managed care organization may |
|
not prohibit, limit, or interfere with a recipient's selection of a |
|
pharmacy or pharmacist of the recipient's choice for the provision |
|
of pharmaceutical services under the plan through the imposition of |
|
different copayments; |
|
(G) that allows the managed care organization or |
|
any subcontracted pharmacy benefit manager to contract with a |
|
pharmacist or pharmacy providers separately for specialty pharmacy |
|
services, except that: |
|
(i) the managed care organization and |
|
pharmacy benefit manager are prohibited from allowing exclusive |
|
contracts with a specialty pharmacy owned wholly or partly by the |
|
pharmacy benefit manager responsible for the administration of the |
|
pharmacy benefit program; and |
|
(ii) the managed care organization and |
|
pharmacy benefit manager must adopt policies and procedures for |
|
reclassifying prescription drugs from retail to specialty drugs, |
|
and those policies and procedures must be consistent with rules |
|
adopted by the executive commissioner and include notice to network |
|
pharmacy providers from the managed care organization; |
|
(H) under which the managed care organization may |
|
not prevent a pharmacy or pharmacist from participating as a |
|
provider if the pharmacy or pharmacist agrees to comply with the |
|
financial terms and conditions of the contract as well as other |
|
reasonable administrative and professional terms and conditions of |
|
the contract; |
|
(I) under which the managed care organization may |
|
include mail-order pharmacies in its networks, but may not require |
|
enrolled recipients to use those pharmacies, and may not charge an |
|
enrolled recipient who opts to use this service a fee, including |
|
postage and handling fees; |
|
(J) under which the managed care organization or |
|
pharmacy benefit manager, as applicable, must pay claims in |
|
accordance with Section 843.339, Insurance Code; |
|
(K) under which the managed care organization or |
|
pharmacy benefit manager, as applicable: |
|
(i) to place a drug on a maximum allowable |
|
cost list, must ensure that: |
|
(a) the drug is listed as "A" or "B" |
|
rated in the most recent version of the United States Food and Drug |
|
Administration's Approved Drug Products with Therapeutic |
|
Equivalence Evaluations, also known as the Orange Book, has an "NR" |
|
or "NA" rating or a similar rating by a nationally recognized |
|
reference; and |
|
(b) the drug is generally available |
|
for purchase by pharmacies in the state from national or regional |
|
wholesalers and is not obsolete; |
|
(ii) must provide to a network pharmacy |
|
provider, at the time a contract is entered into or renewed with the |
|
network pharmacy provider, the sources used to determine the |
|
maximum allowable cost pricing for the maximum allowable cost list |
|
specific to that provider; |
|
(iii) must review and update maximum |
|
allowable cost price information at least once every seven days to |
|
reflect any modification of maximum allowable cost pricing; |
|
(iv) must, in formulating the maximum |
|
allowable cost price for a drug, use only the price of the drug and |
|
drugs listed as therapeutically equivalent in the most recent |
|
version of the United States Food and Drug Administration's |
|
Approved Drug Products with Therapeutic Equivalence Evaluations, |
|
also known as the Orange Book; |
|
(v) must establish a process for |
|
eliminating products from the maximum allowable cost list or |
|
modifying maximum allowable cost prices in a timely manner to |
|
remain consistent with pricing changes and product availability in |
|
the marketplace; |
|
(vi) must: |
|
(a) provide a procedure under which a |
|
network pharmacy provider may challenge a listed maximum allowable |
|
cost price for a drug; |
|
(b) respond to a challenge not later |
|
than the 15th day after the date the challenge is made; |
|
(c) if the challenge is successful, |
|
make an adjustment in the drug price effective on the date the |
|
challenge is resolved and make the adjustment applicable to all |
|
similarly situated network pharmacy providers, as determined by the |
|
managed care organization or pharmacy benefit manager, as |
|
appropriate; |
|
(d) if the challenge is denied, |
|
provide the reason for the denial; and |
|
(e) report to the commission every 90 |
|
days the total number of challenges that were made and denied in the |
|
preceding 90-day period for each maximum allowable cost list drug |
|
for which a challenge was denied during the period; |
|
(vii) must notify the commission not later |
|
than the 21st day after implementing a practice of using a maximum |
|
allowable cost list for drugs dispensed at retail but not by mail; |
|
and |
|
(viii) must provide a process for each of |
|
its network pharmacy providers to readily access the maximum |
|
allowable cost list specific to that provider; and |
|
(L) under which the managed care organization or |
|
pharmacy benefit manager, as applicable: |
|
(i) may not require a prior authorization, |
|
other than a clinical prior authorization or a prior authorization |
|
imposed by the commission to minimize the opportunity for waste, |
|
fraud, or abuse, for or impose any other barriers to a drug that is |
|
prescribed to a child enrolled in the STAR Kids managed care program |
|
for a particular disease or treatment and that is on the vendor drug |
|
program formulary or require additional prior authorization for a |
|
drug included in the preferred drug list adopted under Section |
|
531.072; |
|
(ii) must provide for continued access to a |
|
drug prescribed to a child enrolled in the STAR Kids managed care |
|
program, regardless of whether the drug is on the vendor drug |
|
program formulary or, if applicable on or after August 31, 2023, the |
|
managed care organization's formulary; |
|
(iii) may not use a protocol that requires a |
|
child enrolled in the STAR Kids managed care program to use a |
|
prescription drug or sequence of prescription drugs other than the |
|
drug that the child's physician recommends for the child's |
|
treatment before the managed care organization provides coverage |
|
for the recommended drug; and |
|
(iv) must pay liquidated damages to the |
|
commission for each failure, as determined by the commission, to |
|
comply with this paragraph in an amount that is a reasonable |
|
forecast of the damages caused by the noncompliance; |
|
(24) a requirement that the managed care organization |
|
and any entity with which the managed care organization contracts |
|
for the performance of services under a managed care plan disclose, |
|
at no cost, to the commission and, on request, the office of the |
|
attorney general all discounts, incentives, rebates, fees, free |
|
goods, bundling arrangements, and other agreements affecting the |
|
net cost of goods or services provided under the plan; |
|
(25) a requirement that the managed care organization |
|
not implement significant, nonnegotiated, across-the-board |
|
provider reimbursement rate reductions unless: |
|
(A) subject to Subsection (a-3), the |
|
organization has the prior approval of the commission to make the |
|
reductions; or |
|
(B) the rate reductions are based on changes to |
|
the Medicaid fee schedule or cost containment initiatives |
|
implemented by the commission; and |
|
(26) a requirement that the managed care organization |
|
make initial and subsequent primary care provider assignments and |
|
changes. |
|
SECTION 3. (a) The Health and Human Services Commission |
|
shall, in a contract between the commission and a managed care |
|
organization under Chapter 533, Government Code, that is entered |
|
into or renewed on or after the effective date of this Act, require |
|
that the managed care organization comply with Section |
|
533.005(a)(23)(C-2), Government Code, as added by this Act. |
|
(b) The Health and Human Services Commission shall seek to |
|
amend contracts entered into with managed care organizations under |
|
Chapter 533, Government Code, before the effective date of this Act |
|
to require those managed care organizations to comply with Section |
|
533.005(a)(23)(C-2), Government Code, as added by this Act. To the |
|
extent of a conflict between that section and a provision of a |
|
contract with a managed care organization entered into before the |
|
effective date of this Act, the contract provision prevails. |
|
SECTION 4. If before implementing any provision of this Act |
|
a state agency determines that a waiver or authorization from a |
|
federal agency is necessary for implementation of that provision, |
|
the agency affected by the provision shall request the waiver or |
|
authorization and may delay implementing that provision until the |
|
waiver or authorization is granted. |
|
SECTION 5. This Act takes effect September 1, 2021. |